IL318653A - Intranasal administration of BDNF for the treatment of sensorineural hearing loss - Google Patents

Intranasal administration of BDNF for the treatment of sensorineural hearing loss

Info

Publication number
IL318653A
IL318653A IL318653A IL31865325A IL318653A IL 318653 A IL318653 A IL 318653A IL 318653 A IL318653 A IL 318653A IL 31865325 A IL31865325 A IL 31865325A IL 318653 A IL318653 A IL 318653A
Authority
IL
Israel
Prior art keywords
bdnf
treatment
hearing loss
intranasal administration
sensorineural hearing
Prior art date
Application number
IL318653A
Other languages
English (en)
Hebrew (he)
Inventor
Anna Rita Fetoni
Andrea Aramini
Laura Brandolini
Pasquale Cocchiaro
Tiziana Romeo
Nicola Detta
Lucia Apparente
Simone Mattioli
Franca Cattani
Flavio Mantelli
Marcello Allegretti
Original Assignee
Domp? Farm Spa
Anna Rita Fetoni
Andrea Aramini
Laura Brandolini
Pasquale Cocchiaro
Tiziana Romeo
Nicola Detta
Lucia Apparente
Simone Mattioli
Franca Cattani
Flavio Mantelli
Marcello Allegretti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domp? Farm Spa, Anna Rita Fetoni, Andrea Aramini, Laura Brandolini, Pasquale Cocchiaro, Tiziana Romeo, Nicola Detta, Lucia Apparente, Simone Mattioli, Franca Cattani, Flavio Mantelli, Marcello Allegretti filed Critical Domp? Farm Spa
Publication of IL318653A publication Critical patent/IL318653A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
IL318653A 2022-08-05 2023-08-04 Intranasal administration of BDNF for the treatment of sensorineural hearing loss IL318653A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22189067.6A EP4316462A1 (en) 2022-08-05 2022-08-05 Intranasal administration of bdnf for the treatment of sensorineural hearing loss
PCT/EP2023/071676 WO2024028483A1 (en) 2022-08-05 2023-08-04 Intranasal administration of bdnf for the treatment of sensorineural hearing loss

Publications (1)

Publication Number Publication Date
IL318653A true IL318653A (en) 2025-03-01

Family

ID=83080998

Family Applications (1)

Application Number Title Priority Date Filing Date
IL318653A IL318653A (en) 2022-08-05 2023-08-04 Intranasal administration of BDNF for the treatment of sensorineural hearing loss

Country Status (8)

Country Link
US (1) US20260048006A1 (https=)
EP (2) EP4316462A1 (https=)
JP (1) JP2025525990A (https=)
CN (1) CN119816318A (https=)
AU (1) AU2023317860A1 (https=)
CA (1) CA3263977A1 (https=)
IL (1) IL318653A (https=)
WO (1) WO2024028483A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4623926A1 (en) * 2024-03-26 2025-10-01 Dompe' Farmaceutici SpA Intranasal administration of bdnf for treatment of primary headaches

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2278999B1 (en) * 2008-04-21 2025-01-29 Dompé farmaceutici S.p.A. Auris formulations for treating otic diseases and conditions
WO2019140012A1 (en) * 2018-01-09 2019-07-18 Otonomy, Inc. Growth factor otic formulations
WO2021030452A1 (en) * 2019-08-14 2021-02-18 Decibel Therapeutics, Inc. Permeation enhancers, compositions containing them, and methods of using the same
WO2021151013A1 (en) * 2020-01-24 2021-07-29 Otonomy, Inc. Growth factor formulation for condition associated with otic event
US20240066099A1 (en) * 2020-12-15 2024-02-29 Dompé Farmaceutici S.P.A. Bdnf otic formulations and use thereof

Also Published As

Publication number Publication date
WO2024028483A1 (en) 2024-02-08
EP4565254A1 (en) 2025-06-11
US20260048006A1 (en) 2026-02-19
AU2023317860A1 (en) 2025-02-13
EP4316462A1 (en) 2024-02-07
CN119816318A (zh) 2025-04-11
CA3263977A1 (en) 2024-02-08
JP2025525990A (ja) 2025-08-07

Similar Documents

Publication Publication Date Title
IL318657A (en) Intranasal administration of NGF for the treatment of sensorineural hearing loss
IL318653A (en) Intranasal administration of BDNF for the treatment of sensorineural hearing loss
EP3952882A4 (en) IMMUNO-MODULATORY OLIGOSACCHARIDES FOR PAIN TREATMENT
EP4034240A4 (en) TREATMENT OF TAUOPATHIES
HK40122674A (en) Intranasal administration of ngf for the treatment of sensorineural hearing loss
CA3266348A1 (en) MASSAGE DEVICE
PT4452267T (pt) Derivados de 4-fenil-tetra-hidropiridina para o tratamento de doenças auditivas
IL315627A (en) Azasterone for the treatment of sudden sensorineural hearing loss
AU2023902197A0 (en) Treatment for tinnitus
HK40117061A (en) Azasetron for the treatment of sudden sensorineural hearing loss
CA217747S (en) Hearing aid
AU2023900722A0 (en) Neurogenic Audiological Tinnitus Treatment
CA3296371A1 (en) Intra cochlear administration device
AU2024288814A1 (en) Intra cochlear administration device
GB2626167B (en) Audio therapy
GB202212019D0 (en) Tau therapy
GB202200872D0 (en) Tau therapy
AU2024370739A1 (en) Treatment
AU2024362751A1 (en) Gene therapy for hearing loss and vestibular disorders
GB202303035D0 (en) Hearing aid
HK40115121A (en) Mirdametinib treatment
CA3278874A1 (en) Tobacco treatment
EM87872870003S (sk) Hydroterapeutické prístroje [lekárske prístroje] (časť - )
EM87872870001S (lt) Hidroterapijos aparatai [medicininė aparatūra] (dalis - )
GB202202328D0 (en) Hearing aid